Navigation Links
Proteomic analysis of immunocamouflaged surfaces
Date:5/25/2012

The transfusion of red blood cells (RBC) is a critical component in the treatment of a number of acute and chronic medical problems. Indeed, approximately 75 million units of whole blood (~34 million liters) are annually collected worldwide for processing and eventual transfusion. Despite this massive collection effort, the need for blood constantly exceeds availability due to a combination of collection, manufacturing, storage and biological (i.e., immunological) issues. The immunological issues can often be the most clinically vexing as the RBC has ~300 blood group antigens that could potentially result in alloimmunization and, in rare cases, prevent life saving transfusions. Currently, there are limited options to either prevent blood group alloimmunization or to cost-effectively treat patients with severe alloimmunization.

To this end, the bioengineering of RBCs by the grafting of biocompatible polymers, such as methoxypoly(ethylene glycol) (mPEG), to donor cells is a promising non-pharmacological immunomodulation technology for preventing RBC transfusion reactions. However, due to the labile nature of RBCs, surface-plasma interactions are poorly understood. To overcome the limitations imposed by viable cells, Dr. Mark Scott and his colleagues at the Canadian Blood Services and the University of British Columbia examined plasma adsorption to bare and polymer modified latex beads using fluorescently labeled plasma and proteomic techniques. Their work, entitled "Immunocamouflage of latex surfaces by grafted methoxypoly(ethylene glycol) (mPEG): proteomic analysis of plasma protein adsorption", was published in SCIENCE CHINA Life Sciences 55 (3), 191-201 (2012).

The authors reported that covalent grafting of mPEG to latex beads gave rise to global immunocamouflage of the bead surface resulting in decreased plasma protein adsorption as assessed by flow cytometry, gel electrophoresis and advanced proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) labeling followed by mass spectrometry (MS). The reduction in plasma adsorption occurred because of polymer-mediated thermodynamic steric exclusion and surface charge camouflage. The iTRAQ-MS findings also demonstrated that the grafted polymer prevented surface interactions with plasma proteins involved in the immune recognition of biomaterials and allogeneic cells.

Biologically, the reduced surface-plasma interactions would enhance biocompatibility by camouflaging antigenic sites and preventing the generation of immune recognition signals. The findings of this paper are supportive and predictive of previously reported observations of the immunocamouflage of RBCs and lymphocytes and of the prevention of viral invasion of cells. The knowledge derived from these proteomic studies will help to further define the physical and chemical parameters necessary for efficient immunocamouflage of allogeneic cells, tissues and biomaterials. The practical application of the immunocamouflage technology could have a significant impact on improving the safety of donor cells (e.g., RBCs), tissues and implantable biomaterials in clinical medicine.

Qualitative and quantitative analysis of plasma surface interactions demonstrated the efficacy of immunocamouflage in preventing plasma protein adsorption. Moreover, iTRAQ analysis provided clear evidence for reduced adsorption of proteins associated with the immunological recognition of foreign cells/tissues and biomaterials.


'/>"/>
Contact: Mark D. SCOTT
mdscott@mail.ubc.ca
Science in China Press
Source:Eurekalert  

Related biology news :

1. AMP opposes exclusive licensing of NIH proteomics patent
2. TGens Center for Proteomics selected as Waters Center of Innovation
3. Case Western Reserve and NeoProteomics announce exclusive option
4. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
5. GEN reports on rediscovered technology to bolster proteomics research
6. Protein extremes gain relevance in massive proteomic studies
7. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
8. Reportlinker Adds Proteomics: Technologies and Global Markets Report
9. Proteomics: Finding the key ingredients of disease
10. New manual presents robust, state-of-the-art proteomics methods for teaching and research
11. Proteomics study yields clues as to how tuberculosis might be thwarting the immune system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Proteomic analysis of immunocamouflaged surfaces
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular ... CE Mark its Chlamydia trachomatis (CT) test to be launched ... the IVD Directive (98/79/EC), the CT test is now cleared ... --> The launch of the io® CT ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology: